ARCUS BIOSCIENCES INC

Arcus Biosciences (RCUS) slides 4.24% lower, trading below its 200‑day SMA at $18.54. Explore why investors caution amid immunotherapy race & upcoming clinical data.

Arcus Biosciences sees a 19.6% plunge amid market volatility—investors weigh trial setbacks, competitive pressure, and future partnership prospects.

Arcus Biosciences’ stock slumps 20% as its new public offering raises hopes and risk of dilution—find out how the biotech firm may shift or fall.

Arcus Biosciences’ latest stock rise follows strong casdatifan trial results for clear‑cell kidney cancer, positioning the company as a rising immuno‑oncology contender.